Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Notable gainers during the session included Apple (AAPL), Eli Lilly (LLY), and Walmart (WMT), demonstrating market resilience in certain sectors despite the tech-focused decline. To watch more ...

Eli Lilly and Company (LLY ... indicating a potential upside of 25.7% from the current levels. With headquarters in the heart of Chicago's financial district, Barchart has been an industry ...

Eli Lilly on Tuesday said the company’s revenue in 2024 totaled about $45 billion, a 32% jump on 2023’s total but less than what it had estimated in October. Third quarter sales of Mounjaro and ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation.

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,020.00. Akash Tewari’s rating is based ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...